> About Us

Reason to Believe for the Future

The cardioprotective proteins Forcefield is developing are likely to address other heart disease indications. These proteins have naturally evolved to repair molecular, cellular, and organ damage and consequently have potential in other heart diseases with common aetiology.

Learn More

Building on successful fusion protein application in other therapy areas these proteins will be developed based on well-established protein science and CMC development approaches.

Forcefield has a unique and dominant IP position, with a long patent life and exclusivity to the application of these proteins in the treatment of cardiac disease.

While our initial focus is on myocardial infarction (MI), Forcefield has an exclusive licence to the use of these proteins in the treatment of heart diseases, providing the company with multiple opportunities to add value through partnering and potential collaborations.

Leadership Team

Forcefield’s leadership team has a track record of success in delivering novel discovery biology in cardiovascular disease, biopharmaceutical development and commercialisation, and building successful companies.

Well positioned to move swiftly into the clinic due to the team’s deep and broad expertise in disease biology and development, and backed by a team of industry experts.

John Tsai

Chief Executive Officer

Under the leadership of experienced life sciences executive, John Tsai, MD.

With 20 years of leadership experience in life sciences, John manages organisational leadership and strategy as Chief Executive Officer at Forcefield and as an Executive Partner at Syncona Investment Management Ltd.

He was previously President, Global Drug Development and Chief Medical Officer at Novartis, where he led the Company’s development portfolio across 500 development projects resulting in 20 global drug approvals.

Before joining Novartis, John was Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen and spent 11 years at Bristol-Myers-Squibb, where he held senior leadership positions across both Drug Development and Medical organizations.

A trained physician, John received his medical degree from the University of Louisville School of Medicine and a Bachelor of Science in Electrical Engineering from Washington University in St. Louis.

Prof. Mauro Giacca

Scientific Founder

Founded by authority in cardiovascular disease, Professor Mauro Giacca.

Professor of Cardiovascular Sciences and Head of the School of Cardiovascular Medicine & Sciences, King’s College London.

Fellow of the Academy of Medical Sciences and previously Director-General of the United Nations International Centre for Genetic Engineering and Biotechnology.

Highly cited researcher with over 370 published papers.

Dan Gliddon

Chief Operating Officer

Virtual R&D model managed by biologics development specialist Dan Gliddon, COO.

Over 15 years of biopharmaceutical discovery and development experience in pharma, CRO and biotech.

Former member of exec. leadership team at F-star Therapeutics, leading the clinical translation of their innovative bispecific antibodies, and supporting the company’s corporate development and Nasdaq listing.

Prof. Ajay Shah

Clinical Advisor

Advised by eminent interventional cardiologist, Professor Ajay Shah as Board observer and clinical advisor.

Executive Dean of the Faculty of Life Sciences and Medicine at King’s College London with active research interests in the pathology of heart failure.

Fellow of numerous cardiology societies and editorial boards of several prestigious journals.

Elisa Petris

Board Director

Elisa is a Lead Partner of Syncona Investment Management Ltd.

She is a Director on the Board of Quell Therapeutics, Beacon Therapeutics and Forcefield Therapeutics and was previously on the Board of former portfolio companies Blue Earth Diagnostics and Neogene, and of current portfolio company Achilles Therapeutics. She was closely involved in the foundation of Quell, Blue Earth, Achilles and Beacon including their operational and strategic set-up.

Previously, she was a Senior Associate at Michel Dyens & Co. working on transactions covering the healthcare space, and a member of the Life Science team at L.E.K. Consulting based in London. While at L.E.K. she worked on projects for biotech, pharma and private equity clients. Elisa has a PhD in Molecular Biology from Imperial College and an MBA from London Business School.

Alice Renard

Board Director

Alice is a Partner of Syncona Investment Management Ltd

Alice also works closely with Syncona portfolio company Anaveon. Alice serves as an Observer on the Board of Purespring and Anaveon.

Prior to joining Syncona, Alice was an Investment Banking Analyst within Barclays’ Healthcare Corporate Finance and M&A team, where she worked on transactions involving pharmaceutical and other healthcare companies. Prior to Barclays, Alice worked briefly at AbbVie and Janssen.

Alice holds a Doctorate degree in Pharmacy from the University of Lille 2 in France. Alice also holds a Masters in International Health Policy & Health Economics from the London School of Economics.

Record of Success

A proven team with a record of success from discovery to commercialisation, backed by leading life sciences investment fund, Syncona.

Forcefield operates a virtual business model that allows efficient use of resources and the flexibility to work with strategic and operational partners sharing our purpose. We welcome enquiries from potential partners with expertise to enhance our research and development efforts and deliver therapeutic benefit to heart attack patients quickly.

Backed by Syncona, a leading healthcare company focused on creating, building and scaling a portfolio of global leaders in life science.